EVOTEC SE - SPON ADR (EVO) Stock Price, Forecast & Analysis
USA - NASDAQ:EVO - US30050E1055 - ADR
EVO Key Statistics, Chart & Performance
The current stock price of EVO is 3.35 USD. In the past month the price decreased by -15.95%. In the past year, price decreased by -19.01%.
EVO Latest News, Press Relases and Analysis
EVO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.32 | 214.16B | ||
| DHR | DANAHER CORP | 27.44 | 151.47B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 160.81 | 48.80B | ||
| A | AGILENT TECHNOLOGIES INC | 26.91 | 41.57B | ||
| IQV | IQVIA HOLDINGS INC | 18.06 | 35.70B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.18 | 29.64B | ||
| WAT | WATERS CORP | 28.88 | 21.83B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.77 | 20.22B | ||
| ILMN | ILLUMINA INC | 27.6 | 18.50B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.79 | 16.79B | ||
| TEM | TEMPUS AI INC | N/A | 13.26B | ||
| ICLR | ICON PLC | 12.41 | 12.73B |
Related stock screener links
About EVO
Company Profile
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,759 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Company Info
EVOTEC SE - SPON ADR
Essener Bogen 7
Hamburg HAMBURG DE
CEO: Werner Lanthaler
Employees: 4759
Phone: 4940560810
EVOTEC SE - SPON ADR / EVO FAQ
Can you describe the business of EVOTEC SE - SPON ADR?
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,759 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
What is the current price of EVO stock?
The current stock price of EVO is 3.35 USD. The price increased by 0.15% in the last trading session.
Does EVOTEC SE - SPON ADR pay dividends?
EVO does not pay a dividend.
What is the ChartMill rating of EVOTEC SE - SPON ADR stock?
EVO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does EVOTEC SE - SPON ADR belong to?
EVOTEC SE - SPON ADR (EVO) operates in the Health Care sector and the Life Sciences Tools & Services industry.
What is the expected growth for EVO stock?
The Revenue of EVOTEC SE - SPON ADR (EVO) is expected to decline by -2.27% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
EVO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to EVO. When comparing the yearly performance of all stocks, EVO is a bad performer in the overall market: 84.53% of all stocks are doing better.
EVO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EVO. Both the profitability and financial health of EVO have multiple concerns.
EVO Financial Highlights
Over the last trailing twelve months EVO reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS decreased by -136.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.6% | ||
| ROE | -18.39% | ||
| Debt/Equity | 0.42 |
EVO Forecast & Estimates
13 analysts have analysed EVO and the average price target is 5.51 USD. This implies a price increase of 64.61% is expected in the next year compared to the current price of 3.35.
For the next year, analysts expect an EPS growth of 59.73% and a revenue growth -2.27% for EVO